Table 1.
Characteristics of the 45 AML patients at diagnosis
|
All patients |
FISH + CD34 + CD38- |
FISH + CD34 + CD38- |
P value | |
|---|---|---|---|---|
| N = 45 |
<1% |
≥1% |
||
| N = 20 | N = 25 | |||
| Gender |
|
|
|
|
| Male(%) |
25(55.6) |
10(50) |
15(60) |
0.557 |
| Female(%) |
20(44.4) |
10(50) |
10(40) |
|
| Age, Median(range) |
42(14–71) |
36(19–71) |
45(14–66) |
0.5600 |
| WBC, Median(range) |
14.5(0.63-143) |
12.4(0.63-125.24) |
14.9(1.7-143) |
0.9091 |
| PLT, Median(range) |
42(4–191) |
28(4–191) |
48(16–157) |
0.198 |
| BM blast% |
58(18–96) |
52.5(20–94.5) |
62(18–96) |
0.265 |
| FAB subtype |
|
|
|
0.694 |
| M1 |
5 |
2 |
3 |
|
| M2 |
18 |
10 |
8 |
|
| M4 |
12 |
5 |
7 |
|
| M5 |
9 |
3 |
6 |
|
| M6 |
1 |
0 |
1 |
|
| Cytogenetics risk |
|
|
|
0.894 |
| Favorable |
24 |
10 |
14 |
|
| Intermediate |
12 |
6 |
6 |
|
| Poor |
9 |
4 |
5 |
|
| FLT3 mutations (%) |
5(11.1) |
2(10) |
3(12) |
1 |
| Allo-HSCT(%) | 14(31.1) | 6(30) | 8(32) | 1 |
Patients were stratified into favorable (cases with t(8;21), or inv(16), excluding complex cytogenetic), poor (cases with complex cytogenetic changes three or more unrelated abnormalities, t(6;9) or 11q23 abnormalities [excluding t(9;11)]), and intermediate (cases with t(9;11), trisomy 8, 7q-, 9q-, or trisomy 21) risk groups.